Efficacy and safety of high-intensity focused ultrasound ablation for hepatocellular carcinoma by changing the acoustic environment: microbubble contrast agent (SonoVue) and transcatheter arterial chemoembolization

Huang, Lihui; Zhou, Kun; Zhang, Jun; Ma, Yuhong; Yang, Wei; Ran, Lifeng; Chen, Jin; Dimitrov, Dobromir; Zhu, Hui

doi:10.1080/02656736.2018.1558290

Cited by 23 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been tremendous improvements in HCC therapy during the last two decades, especially in the use of minimal interventional therapies (Facciorusso et al, 2016;Salati et al, 2017;Shiina et al, 2018). Microwave ablation is one such method that has shown promising outcomes for HCC treatment, due to the rapid temperature increase and larger ablation compared with other modalities (Zhang et al, 2019). Despite being a promising technique for HCC ablation, MWA faces some challenges, including the limited ablation zone and the thermal injury risk for adjacent visceral tissues (Facciorusso et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…Surgery is not always an option among patients with liver cancer as concurrent liver cirrhosis, which many of these patients have, increases the risk of mortality (Johnson and Wright, 2019). Minimally invasive therapies, such as radiofrequency ablation or microwave ablation (MWA) and high-intensity focused ultrasound ablation, offer new therapeutic approaches for HCC, (Zhu et al, 2018;Lyu et al, 2018;Mu et al, 2018;Huang et al, 2019) with the advantages of lower morbidity and mortality and broader indications compared with surgery (Shiina et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

“…Nanoparticles as a drug delivery system has brought great improvements to cancer therapy (Dong et al, 2019). Nanoparticle therapeutics, based on natural or synthetic organic geo-macromolecules, have been developed as drug delivery systems by extending circulation times and facilitating uptake into tumors via enhanced permeability and retention (EPR) effect caused by leaky tumor vasculature (Yang et al, 2019). Liposomes were first approved by the US Food and Drug Administration and, since then, have attracted tremendous attention due to their high payload and easy synthesis, facilitating increased drug accumulation at tumor sites (Jha et al, 2016;Wang et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Chemotherapeutic Nanoparticle-Based Liposomes Enhance the Efficiency of Mild Microwave Ablation in Hepatocellular Carcinoma Therapy

Zhang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer, and the 5-year overall survival (OS) rate for HCC remains unsatisfying worldwide. Microwave ablation (MWA) is a minimally invasive therapy that has made progress in treating HCC. However, HCC recurrence remains problematic. Therefore, combination therapy may offer better outcomes and enhance MWA efficiency through improved tumor control. We have developed doxorubicin-loaded liposomes (DNPs) as an efficient nanoplatform to enhance MWA of hepatocellular carcinoma even at the mild ablation condition. In this study, we demonstrated that the uptake of DNPs by HCC cells was increased 1.5-fold compared with that of free DOX. Enhanced synergism was observed in the combination of DNPs and MWA, which induced nearly 80% cell death. The combination of mild MWA and DNPs enhanced the ablation efficiency of HCC with significant inhibition of liver tumors and accounted for the longest survival rate among all groups. A much higher accumulation of the DNPs was observed in the transitional zone than in the ablation zone. No apparent systemic toxicity was observed for any of the treatments after 14 days. The present work demonstrates that DNPs combined with MWA could be a promising nanoparticle-based therapeutic approach for the treatment of hepatocellular carcinoma and shows potential for future clinical applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapeutic Nanoparticle-Based Liposomes Enhance the Efficiency of Mild Microwave Ablation in Hepatocellular Carcinoma Therapy

Zhang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Finally, CEUS has proven to be a very safe imaging modality. 15,19,20,29 The EFSUMB guidelines approve its use in several organ systems such as the endocrine, lymphatic, gastrointestinal, and genitourinary systems, among others. 29 The microbubbles are excreted via the lung and the liver, which makes CEUS a safe and useful technique in patients with kidney disease.…”

Section: Advantagesmentioning

confidence: 99%

The role of contrast-enhanced ultrasound in neurosurgical disease

Kearns

Sokolowski

Chadwell

et al. 2019

Neurosurgical Focus

View full text Add to dashboard Cite

Contrast-enhanced ultrasound (CEUS) is a relatively new imaging modality in the realm of neurosurgical disease. CEUS permits the examination of blood flow through arteries, veins, and capillaries via intravascular contrast agents and allows vascular architectural mapping with extreme sensitivity and specificity. While it has established utility in other organ systems such as the liver and kidneys, CEUS has not been studied extensively in the brain. This report presents a review of the literature on the neurosurgical applications of CEUS and provides an outline of the imaging modality’s role in the diagnosis, evaluation, and treatment of neurosurgical disease.

show abstract

“…HIFU monotherapy (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33) could achieve great tumor response with 1-year survival rates of approximately 80%. When combined with transarterial chemoembolization (TACE) (34)(35)(36)(37)(38)(39)(40)(41)(42), the results were roughly equal to that of HIFU monotherapy. HIFU local therapy for MLC patients has also been evaluated by several clinical trials (20,24,(43)(44)(45)(46)(47).…”

Section: Introductionmentioning

confidence: 99%

High-Intensity Focused Ultrasound Ablation for Unresectable Primary and Metastatic Liver Cancer: Real-World Research in a Chinese Tertiary Center With 275 Cases

Zhu

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

This retrospective analysis was conducted to evaluate the feasibility and safety of highintensity focused ultrasound ablation for primary liver cancer and metastatic liver cancer. Patients with liver cancer who received high-intensity focused ultrasound were included in this analysis, including a primary liver cancer cohort (n=80) and a metastatic liver cancer cohort (n=195). The primary endpoint of our research was tumor response. The secondary endpoints included survival outcomes, visual analog scale pain scores, alpha-fetoprotein relief, and complications. Objective response rate and disease control rate were observed to be 71.8% and 81.2%, respectively, in patients with primary liver cancer and were 63.7% and 83.2% in cases with metastatic liver cancer. Alphafetoprotein levels and visual analogue scale levels significantly decreased after treatment compared with the baseline levels in patients with primary liver cancer (p<0.05). Median overall survival was estimated to be 13.0 and 12.0 months in the primary liver cancer and metastatic liver cancer cohorts. The 1-year survival rate was 70.69% and 48.00%, respectively. Multivariate regression analysis showed that visual analogue scale ≥ 5, longest diameter ≥ 5 cm, and portal vein invasion were the independent risk factors for poor survival in primary liver cancer. For patients with metastatic liver cancer, independent risk factors were identified as visual analogue scale ≥ 5, longest diameter ≥ 5 cm, existence of extrahepatic metastases, existence of portal vein invasion, and time to high-intensity focused ultrasound treatment from diagnosis < 3 months. Severe adverse events were rarely reported. In conclusion, high-intensity focused ultrasound might be an effective and safe option for patients with liver cancer regardless of primary and metastatic lesions.

show abstract

Efficacy and safety of high-intensity focused ultrasound ablation for hepatocellular carcinoma by changing the acoustic environment: microbubble contrast agent (SonoVue) and transcatheter arterial chemoembolization

Abstract: Zhu (2019) Efficacy and safety of high-intensity focused ultrasound ablation for hepatocellular carcinoma by changing the acoustic environment: microbubble contrast agent (SonoVue) and transcatheter arterial chemoembolization, International

Cited by 23 publications

References 33 publications

Chemotherapeutic Nanoparticle-Based Liposomes Enhance the Efficiency of Mild Microwave Ablation in Hepatocellular Carcinoma Therapy

Chemotherapeutic Nanoparticle-Based Liposomes Enhance the Efficiency of Mild Microwave Ablation in Hepatocellular Carcinoma Therapy

The role of contrast-enhanced ultrasound in neurosurgical disease

High-Intensity Focused Ultrasound Ablation for Unresectable Primary and Metastatic Liver Cancer: Real-World Research in a Chinese Tertiary Center With 275 Cases

Contact Info

Product

Resources

About